# A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

> **NCT06928376** · PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 160 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- First Line Therapy

## Interventions

- **DRUG:** Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
- **DRUG:** "3+7"

## Key facts

- **NCT ID:** NCT06928376
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-18
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06928376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06928376, "A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06928376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*